Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human Phase I trial assessing safety, tolerability and immunomodulatory effects of Foralumab in healthy volunteers

Next Previous
X
Search
Trial Profile

A first-in-human Phase I trial assessing safety, tolerability and immunomodulatory effects of Foralumab in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Foralumab (Primary)
  • Indications Amyotrophic lateral sclerosis; Multiple sclerosis; Neurodegenerative disorders
  • Focus Adverse reactions; First in man; Proof of concept

    • Most Recent Events

    • 23 Nov 2022 According to a Tiziana Life Sciences media release, data from this study published in Frontiers in Immunology
    • 23 Nov 2022 Results published in the Tiziana Life Sciences Media Release
    • 26 May 2021 Results published in the Tiziana Life Sciences Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top